BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:NEO212 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of NEO212\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06047379-2638@assetmemo.bio
DTSTAMP:20261121T005451Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:NEO212: Phase 1/2 readout est. (NCT06047379)
DESCRIPTION:NEO212\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: Safety
  and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant\, Glioblas
 toma IDH-wildtype or Brain Metastasis\nEstimated primary completion: 28 Fe
 bruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/neo212#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06047
 379
URL:https://assetmemo.bio/drug/neo212#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
